Olema Pharma Files Routine 8-K, Confirms Nasdaq Listing
Ticker: OLMA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $5,000,000 m |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, administrative
TL;DR
**Olema Pharma filed a standard 8-K, no major news.**
AI Summary
Olema Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its status as a publicly traded company on The Nasdaq Global Select Market under the ticker OLMA. This filing primarily serves to update administrative details and confirm compliance with SEC regulations, rather than announcing a specific material event. For investors, this filing is a routine update, indicating no immediate significant changes to the company's operations or financial standing that would directly impact stock value.
Why It Matters
This is a routine administrative filing, indicating no new material events that would immediately impact Olema Pharmaceuticals' stock price or business operations. It confirms the company's ongoing compliance and listing on Nasdaq.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing and does not disclose any new risks or material events for Olema Pharmaceuticals, Inc.
Analyst Insight
A smart investor would recognize this as a non-event filing, confirming basic corporate information and compliance. No immediate action is warranted based solely on this routine 8-K.
Key Players & Entities
- Olema Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Olema Pharmaceuticals' common stock is registered
- OLMA (company) — the trading symbol for Olema Pharmaceuticals, Inc.
- January 08, 2024 (date) — the date of the earliest event reported in the 8-K
- 001-39712 (other) — Commission File Number for Olema Pharmaceuticals, Inc.
FAQ
What is the purpose of Olema Pharmaceuticals, Inc.'s 8-K filing dated January 08, 2024?
The 8-K filing by Olema Pharmaceuticals, Inc. on January 08, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily serving as a Regulation FD Disclosure and 'Other Events' disclosure, indicating a routine administrative update rather than a specific material event.
On which stock exchange is Olema Pharmaceuticals, Inc.'s common stock registered?
Olema Pharmaceuticals, Inc.'s Common Stock, par value $0.0001 per share, is registered on The Nasdaq Global Select Market, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the trading symbol for Olema Pharmaceuticals, Inc.?
The trading symbol for Olema Pharmaceuticals, Inc. is OLMA, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the 8-K filing.
What is the business address of Olema Pharmaceuticals, Inc. as listed in the filing?
The business address of Olema Pharmaceuticals, Inc. is 780 Brannan Street, San Francisco, California, 94103, according to the 'BUSINESS ADDRESS' section of the filing.
Does this 8-K filing indicate that Olema Pharmaceuticals, Inc. is an emerging growth company?
The filing includes a checkbox for 'emerging growth company' but does not explicitly check it, nor does it provide further information on this status. The form asks the registrant to 'Indicate by check mark whether the registrant is an emerging growth company'.
Filing Stats: 1,028 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2024-01-08 08:18:51
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se
- $5,000,000 m — f June 7, 2022, the Company will make a $5,000,000 milestone payment to Aurigene upon the in
Filing Documents
- olma-20240108.htm (8-K) — 46KB
- olma-ex99_1.htm (EX-99.1) — 14KB
- 0000950170-24-002721.txt ( ) — 177KB
- olma-20240108.xsd (EX-101.SCH) — 24KB
- olma-20240108_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 8, 2024, Olema Pharmaceuticals, Inc. (the “Company”) announced the selection of a development candidate for the Company’s program targeting KAT6, an epigenetic target that is dysregulated in breast cancer and other cancers. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. As described above, on January 8, 2024, the Company announced the selection of a development candidate for the Company’s program targeting KAT6, an epigenetic target that is dysregulated in breast cancer and other cancers. The compound, named OP-3136, is an orally bioavailable, potent KAT6A/B-selective inhibitor developed by Olema in collaboration with Aurigene Oncology (“Aurigene”). The Company presented data regarding the discovery and pre-clinical development of its KAT6 program in a poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. OP-3136 is orally bioavailable in multiple non-clinical species with desirable pharmacokinetics and has demonstrated highly selective and potent activity against KAT6A and KAT6B versus other KAT family members. In KAT6-amplified and overexpressing estrogen receptor-positive (“ER+”) breast cancer cell lines, OP-3136 strongly inhibited cell proliferation whereas KAT6-low cell lines were insensitive to the compounds. In a non-clinical xenograft model, OP-3136 caused dose-dependent tumor growth inhibition and tumor regression comparable to or better than a positive-control patented KAT6 inhibitor and demonstrated synergy in combination with CDK4/6 inhibitors or palazestrant (OP-1250). Olema is initiating non-clinical Investigational New Drug (“IND”) enabling studies in order to support a potential IND submission to the U.S. Food and Drug Administration for OP-3136 by the end of 2024. Pursuant to the Drug Discovery Collaboration and License Agreement by and between the Company and Aurigene, dated as of June 7, 2022, the Company will make a $5,000,000 milestone payment to Aurigene upon the initiation of IND-enabling studies.
Forward Looking Statements
Forward Looking Statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 8, 2024, of Olema Pharmaceuticals, Inc . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Olema Pharmaceuticals, Inc. Date: January 8, 2024 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer